US SB909 | 2021-2022 | 117th Congress


Spectrum: Moderate Partisan Bill (Democrat 6-1)
Status: Introduced on March 23 2021 - 25% progression
Action: 2021-03-23 - Committee on Health, Education, Labor, and Pensions Subcommittee on Primary Health and Retirement Security. Hearings held.
Text: Latest bill text (Introduced) [PDF]


Establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug. Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population. The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.


Prescription Drug Price Relief Act of 2021



2021-03-23SenateCommittee on Health, Education, Labor, and Pensions Subcommittee on Primary Health and Retirement Security. Hearings held.
2021-03-23SenateRead twice and referred to the Committee on Health, Education, Labor, and Pensions.

Same As/Similar To

HB2148 (Same As) 2021-10-19 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.


US Congress State Sources

Bill Comments